🔗 Visit the ClinicalTrials.gov page for NCT01979536
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | ALK-driven tumors and targeted therapy: focus on crizotinib. | Pharmgenomics Pers Med | 2014 | 0.95 |
| 2 | Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. | J Clin Oncol | 2015 | 0.88 |
| 3 | Remaining challenges in childhood cancer and newer targeted therapeutics. | Pediatr Clin North Am | 2014 | 0.87 |
| 4 | Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. | Clin Cancer Res | 2015 | 0.82 |
| 5 | Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. | Onco Targets Ther | 2014 | 0.80 |
| 6 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |
| 7 | Paediatric non-Hodgkin lymphoma - perspectives in translational biology. | Br J Haematol | 2016 | 0.75 |